Eurofins Advinus Limited
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Eurofins Advinus Limited
Takeda's recent deals include a license in Asian for Tesaro's PARP inhibitor Zejula. Meanwhile, Japanese rival Mitsubishi Tanabe is paying roughly $1bn to acquire Israel's NeuroDerm.
Takeda tantalizingly disclosed during its third quarter results that it has set aside funds for an acquisition worth around $450m in an undisclosed emerging market. What are the likely targets?
Life appears to have come full circle for Advinus Therapeutics' co-founder and former CEO and managing director, Dr. Rashmi Barbhaiya, who recently moved back to the US from India. It has been a bitter-sweet journey with peaks and troughs, although the man himself would rather see any lows as "lessons learned" that come with the territory.
Whether or not it's a rejig in the normal course of business isn't very clear but Japanese giant Takeda has "realigned" certain teams as it pursues plans to provide sustainable access to its medicines under a new leadership in India.
- Contract Research, Toxicology Testing-CRO
- Drug Discovery Tools
- Other Names / Subsidiaries
- Advinus Therapeutics Limited
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.